SLP - Simulations Plus Inc Book Valuation of Business

The current price chart for Simulations Plus, Inc. (SLP) reflects the dynamics of the scientific IT environment, where GastroPlus software is recognized as the gold standard for drug certification, ensuring absolute loyalty from the FDA regulator. The business model relies on the pharmaceutical industry's need for digital testing, with the indicator standing at 0.14. Innovations are based on the application of AI to simulate drug effects on the body, which significantly reduces the development timelines for new medications.

The capital stability of Simulations Plus (SLP) depends directly on the efficiency of its unique technological solutions. This indicator measures the difference between total assets and liabilities, determining the real value of equity. By analyzing the history of net assets at book value, an investor can see the business's resilience during the intervals between reports. The resource base supports the hiring of AI experts to strengthen the company's monopoly software. Growth in this metric confirms the protection of investments against inflationary risks.